Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has inked a comarketing agreement focused on computational genetic analysis and trait optimization for cannabis and psychedelics. The agreement was signed through Delic Labs, which inked the deal with GTR Research Inc. (“GTR”). GTR is leading out in applying cutting-edge computational and biotech to cannabis and psychedelics. According to the company, Delic Labs will provide genetic analysis of psychedelic mushrooms and cannabis to producers in Canada; the analysis will include sample preparation, DNA extraction, whole-genome sequencing, computational analysis and reporting, as well as detailed information regarding  specific areas of the genome relating to traits of highest commercial interest. A federally authorized psilocybin and cannabis research laboratory, Delic Labs specializes in extraction, analytical testing and chemical process development. The facility is one of only a handful of licensed psilocybin research labs in Canada with clients that include some of the largest brands in the world. “Partnering with GTR will give us the most comprehensive genomic insights in the industry and build on our efforts to provide the highest standards and quality control for psychedelic and cannabis compounds,” said Delic Labs cofounder Dr. Markus Roggen in the press release. “As demand continues to grow for healthier, more effective alternatives to traditional medicines, our combined knowledge will offer producers new, best-in-class products to serve their markets.”

To view the full press release, visit https://ibn.fm/TWu5C

About Delic Corp Inc.

Delic is the leading psychedelic wellness platform, committed to addressing the mental health crisis by increasing access to science-backed benefits for all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including as Reality Sandwich and Delic Radio, trusted media and e-commerce platforms; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and the largest chain of psychedelic wellness clinics in the country, with Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition). Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit www.DelicCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.